These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 32227211)

  • 21. Long-term Follow-up of Hematopoietic Stem Cell Transplant Survivors: A Focus on Screening, Monitoring, and Therapeutics.
    Saunders IM; Tan M; Koura D; Young R
    Pharmacotherapy; 2020 Aug; 40(8):808-841. PubMed ID: 32652612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive Functioning in Survivors of Hematopoietic Stem Cell Transplantation Compared With a Matched General Population Sample-The Maastricht Observational Study of Late Effects After Stem Cell trAnsplantation Study.
    Wauben B; van der Poel MWM; Greevenbroek MMJ; van Yperen NC; Schram MT; van Boxtel MPJ; Sastry M; Simons SO; Stehouwer CDA; Dagnelie PC; Wesselius A; Schouten HC; Köhler S
    Transplant Cell Ther; 2023 Jul; 29(7):468.e1-468.e8. PubMed ID: 36966872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The preventive health behaviors of long-term survivors of cancer and hematopoietic stem cell transplantation compared with matched controls.
    Bishop MM; Lee SJ; Beaumont JL; Andrykowski MA; Rizzo JD; Sobocinski KA; Wingard JR
    Biol Blood Marrow Transplant; 2010 Feb; 16(2):207-14. PubMed ID: 19781657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
    Ghosh N; Karmali R; Rocha V; Ahn KW; DiGilio A; Hari PN; Bachanova V; Bacher U; Dahi P; de Lima M; D'Souza A; Fenske TS; Ganguly S; Kharfan-Dabaja MA; Prestidge TD; Savani BN; Smith SM; Sureda AM; Waller EK; Jaglowski S; Herrera AF; Armand P; Salit RB; Wagner-Johnston ND; Fuchs E; Bolaños-Meade J; Hamadani M
    J Clin Oncol; 2016 Sep; 34(26):3141-9. PubMed ID: 27269951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.
    Robin M; Porcher R; De Castro Araujo R; de Latour RP; Devergie A; Rocha V; Larghero J; Adès L; Ribaud P; Mary JY; Socié G
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1304-12. PubMed ID: 17950917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.
    Ito A; Kim SW; Matsuoka KI; Kawakita T; Tanaka T; Inamoto Y; Toubai T; Fujiwara SI; Fukaya M; Kondo T; Sugita J; Nara M; Katsuoka Y; Imai Y; Nakazawa H; Kawashima I; Sakai R; Ishii A; Onizuka M; Takemura T; Terakura S; Iida H; Nakamae M; Higuchi K; Tamura S; Yoshioka S; Togitani K; Kawano N; Suzuki R; Suzumiya J; Izutsu K; Teshima T; Fukuda T
    Int J Hematol; 2020 Nov; 112(5):674-689. PubMed ID: 32748216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level.
    Fingrut W; Law A; Lam W; Michelis FV; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
    Ann Hematol; 2021 Mar; 100(3):789-798. PubMed ID: 33415423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.
    Smith SM; Godfrey J; Ahn KW; DiGilio A; Ahmed S; Agrawal V; Bachanova V; Bacher U; Bashey A; Bolaños-Meade J; Cairo M; Chen A; Chhabra S; Copelan E; Dahi PB; Aljurf M; Farooq U; Ganguly S; Hertzberg M; Holmberg L; Inwards D; Kanate AS; Karmali R; Kenkre VP; Kharfan-Dabaja MA; Klein A; Lazarus HM; Mei M; Mussetti A; Nishihori T; Ramakrishnan Geethakumari P; Saad A; Savani BN; Schouten HC; Shah N; Urbano-Ispizua A; Vij R; Vose J; Sureda A; Hamadani M
    Cancer; 2018 Jun; 124(12):2541-2551. PubMed ID: 29645093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
    Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
    Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
    Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study.
    Vu DL; Dayer JA; Masouridi-Levrat S; Combescure C; Boely E; Khanna N; Mueller NJ; Kleber M; Medinger M; Halter J; Passweg J; Müller AM; Schanz U; Chalandon Y; Neofytos D; van Delden C; Kaiser L;
    Transpl Infect Dis; 2020 Aug; 22(4):e13289. PubMed ID: 32277837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation.
    Majhail NS; Challa TR; Mulrooney DA; Baker KS; Burns LJ
    Biol Blood Marrow Transplant; 2009 Sep; 15(9):1100-7. PubMed ID: 19660723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance limitations and participation restrictions among childhood cancer survivors treated with hematopoietic stem cell transplantation: the bone marrow transplant survivor study.
    Ness KK; Bhatia S; Baker KS; Francisco L; Carter A; Forman SJ; Robison LL; Rosenthal J; Gurney JG
    Arch Pediatr Adolesc Med; 2005 Aug; 159(8):706-13. PubMed ID: 16061776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the Influence of Different Comorbidities Indexes on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in a Developing Country.
    Teixeira GM; Bittencourt H; de Macedo AV; Martinho GH; Colosimo EA; Rezende SM
    PLoS One; 2015; 10(9):e0137390. PubMed ID: 26394228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Old and new cancers after hematopoietic-cell transplantation.
    Majhail NS
    Hematology Am Soc Hematol Educ Program; 2008; ():142-9. PubMed ID: 19074072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.
    Epperla N; Ahn KW; Litovich C; Ahmed S; Battiwalla M; Cohen JB; Dahi P; Farhadfar N; Farooq U; Freytes CO; Ghosh N; Haverkos B; Herrera A; Hertzberg M; Hildebrandt G; Inwards D; Kharfan-Dabaja MA; Khimani F; Lazarus H; Lazaryan A; Lekakis L; Murthy H; Nathan S; Nishihori T; Pawarode A; Prestidge T; Ramakrishnan P; Rezvani AR; Romee R; Shah NN; Sureda A; Fenske TS; Hamadani M
    J Hematol Oncol; 2019 Jan; 12(1):6. PubMed ID: 30630534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation.
    Shibasaki Y; Suwabe T; Katagiri T; Tanaka T; Kobayashi H; Fuse K; Ushiki T; Sato N; Yano T; Kuroha T; Hashimoto S; Narita M; Furukawa T; Sone H; Masuko M
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28871665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Value of the Hematopoietic Cell Transplantation Comorbidity Index for Patients Undergoing Reduced-Intensity Conditioning Cord Blood Transplantation.
    Salit RB; Oliver DC; Delaney C; Sorror ML; Milano F
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):654-658. PubMed ID: 28189904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.
    Holtan SG; DeFor TE; Lazaryan A; Bejanyan N; Arora M; Brunstein CG; Blazar BR; MacMillan ML; Weisdorf DJ
    Blood; 2015 Feb; 125(8):1333-8. PubMed ID: 25593335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation.
    Kliman D; Nivison-Smith I; Gottlieb D; Hamad N; Kerridge I; Purtill D; Szer J; Ma D
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1711-1718. PubMed ID: 32194285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.